Oncology Xagena
The highly selective TRK inhibitor Larotrectinib ( Vitrakvi ) is approved for the treatment of adult and pediatric cancers that harbor NTRK gene fusions; it achieves a 79% overall response rate ( ORR ...
Papillary renal cell carcinoma ( PRCC ) is the most common type of non-clear cell RCC, accounting for 10–15% of renal malignancies. As a subset of PRCC cases are MET-driven, MET inhibition may be an ...
Pembrolizumab ( Keytruda ) was approved for the treatment of high-risk ( HR ) non–muscle-invasive bladder cancer ( NMIBC ) based on results from the phase 2 KEYNOTE-057 trial. Researchers have pre ...
Patients with advanced B3 thymoma ( B3T ) and thymic carcinoma ( TC ) resistant to chemotherapy have limited treatment options. Treatment with anti-PD1 showed not negligible toxicity and limited act ...
Erdafitinib ( Balversa ) is a pan-FGFR kinase inhibitor for treatment of adults with metastatic urothelial carcinoma ( mUC ) with susceptible FGFR3/2 alterations and who progressed on 1 line or more o ...
In the phase 3, randomized, open-label CASPIAN study, first-line Durvalumab ( Imfinzi ) added to Etoposide plus either Cisplatin or Carboplatin ( EP ) significantly has improved overall survival ( OS ...
Myeloid-derived suppressor cells ( MDSC ) are expanded in cancer and promote immune suppression. A research has shown that Ibrutinib ( Imbruvica ) inhibits migration and immunosuppressive function o ...
NTRK gene fusions lead to transcription of chimeric TRK proteins with overexpressed kinase function. Entrectinib ( Rozlytrek ) is a potent inhibitor of TRKA/B/C. In phase 1/2 studies ( ALKA, STARTRK ...
SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and a prostate-specific antigen ( PSA ) doubling time of les ...
In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, Capmatinib ( Tabrecta ) has shown efficacy in METex14–mutated non–small cell lung cancer ( NSCLC ) patients who were pretreated ( cohort 4 ) ...
While studies have demonstrated survival benefits of first-line regimens including immuno-oncology agents ( IO ) in advanced renal cell carcinoma ( aRCC ), optimal treatment following onco-immunothera ...
KEYNOTE-427, a single-arm, open-label, phase 2 study, has shown antitumor activity with first-line Pembrolizumab ( Keytruda ) monotherapy in non-clear cell renal cell carcinoma ( nccRCC ) ( cohort B ) ...
TAPUR ( Targeted Agent and Profiling Utilization Registry ) is a phase II basket study evaluating anti-tumor activity of targeted agents in patients with advanced cancers with genomic alterations. R ...
First-line treatment with an EGFR tyrosine kinase inhibitor ( TKI ) is standard of care for patients with EGFR-mutated non-small-cell lung cancer ( NSCLC ). The EGFR TKI Osimertinib ( Tagrisso ) is ...
Cabozantinib ( Cabometyx ) may enhance response to immune checkpoint inhibitors ( ICIs ) by promoting an immune-permissive microenvironment and has shown encouraging activity in combination with ICIs ...
